How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Abstract: The performance of the recursive least-squares (RLS) algorithm is governed by the forgetting factor. This parameter leads to a compromise between (1) the tracking capabilities and (2) the ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Recursion is prioritising high-impact drug programmes. Credit: Just_Super via Getty Images. AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...